A potential strategy for this endeavour may include assessment of HER2 status, particularly in light of the connections between FASN expression and signalling downstream of HER2, which have been discussed earlier in this review.82 Indeed, there are now two clinical trials in Phase 2 stages evaluating the combinatorial effects of TVB-2640 and chemotherapy in HER2-positive breast cancer (Clinical Trial ID: NCT03179904) and astrocytomas (Clinical Trial ID: NCT03032484).205. Here, ERBB2 is linked to breast carcinoma.